XML 42 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Narrative) (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 28, 2021
Jun. 30, 2021
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2019
Feb. 16, 2021
Feb. 09, 2021
Dec. 31, 2020
Summary Of Significant Accounting Policies [Line Items]                      
Continuation Advances       $ 34,000,000.0 $ 18,000,000.0            
Period in which company must repay continuation advances if change-of-control transaction is entered into with third party       2 years   2 years          
Equity or debt financing that must be raised in a single transaction       $ 100,000,000   $ 100,000,000          
Period in which company must raise equity or debt financing in a single transaction       2 years              
Contingent repayment liability       $ 0             $ 0
Gain (loss) from Continuation Advances       $ 34,000,000.0   (52,000,000) $ 34,000,000 $ 18,000,000.0      
Continuation Advances paid $ 52,000,000.0                    
Fair value assets/liabilities transfer between levels           $ 0          
Sales Revenue, Net [Member] | Gene Company Limited [Member] | Customer Concentration Risk [Member]                      
Summary Of Significant Accounting Policies [Line Items]                      
Concentration risk, percentage   17.00% 15.00%     14.00% 11.00%        
Convertible Senior Notes [Member]                      
Summary Of Significant Accounting Policies [Line Items]                      
Principal amount of notes $ 900,000,000                 $ 900,000,000  
Debt instrument, stated interest rate 1.50%               1.50%    
Maturity date           Feb. 15, 2028